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Objectives We sought to determine the risk of late stent thrombosis (ST) during long-term follow-up beyond 3 years,
searched for predictors, and assessed the impact of ST on overall mortality.
Background Late ST was reported to occur at an annual rate of 0.6% up to 3 years after drug-eluting stent (DES) implantation.
Methods A total of 8,146 patients underwent percutaneous coronary intervention with a sirolimus-eluting stent (SES)
(n  3,823) or paclitaxel-eluting stent (PES) (n  4,323) and were followed up to 4 years after stent implanta-
tion. Dual antiplatelet treatment was prescribed for 6 to 12 months.
Results Definite ST occurred in 192 of 8,146 patients with an incidence density of 1.0/100 patient-years and a cumula-
tive incidence of 3.3% at 4 years. The hazard of ST continued at a steady rate of 0.53% (95% confidence
interval [CI]: 0.44 to 0.64) between 30 days and 4 years. Diabetes was an independent predictor of early ST
(hazard ratio [HR]: 1.96; 95% CI: 1.18 to 3.28), and acute coronary syndrome (HR: 2.21; 95% CI: 1.39 to
3.51), younger age (HR: 0.97; 95% CI: 0.95 to 0.99), and use of PES (HR: 1.67; 95% CI: 1.08 to 2.56) were
independent predictors of late ST. Rates of death and myocardial infarction at 4 years were 10.6% and
4.6%, respectively.
Conclusions Late ST occurs steadily at an annual rate of 0.4% to 0.6% for up to 4 years. Diabetes is an independent predic-
tor of early ST, whereas acute coronary syndrome, younger age, and PES implantation are associated with late
ST. (J Am Coll Cardiol 2008;52:1134–40) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.006d
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yrug-eluting stents (DES) reduce angiographic restenosis
nd the clinical need for repeat revascularization procedures
1,2). Recent systematic reviews and large-scale registries
bserved similar rates of death and myocardial infarction
MI) for patients treated with either a DES or bare-metal
tent (BMS) during long-term 4-year follow-up (3–5).
owever, very late stent thrombosis (ST) has emerged as a
rom the *Department of Cardiology and †Institute of Social and Preventive
edicine, University of Bern, Bern, Switzerland; and the ‡Department of Interven-
ional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the
etherlands. The study was supported by research grants from the University
ospital Bern, Switzerland, and the Thoraxcenter, Rotterdam, the Netherlands. As
rincipal investigators, Profs. Windecker and Serruys, had full access to the data and
ake the final responsibility for the data as presented in the article. No external
ponsorship was used to cover the costs related to the analysis described in the present
tudy; the authors considered this task as part of their academic assignment. The first
wo authors contributed equally to this work.o
Manuscript received March 18, 2008; revised manuscript received June 30, 2008,
ccepted July 1, 2008.istinct entity overshadowing the use of DES, and concerns
ersist as to whether this phenomenon might jeopardize the
ong-term outcome after DES implantation, particularly
fter discontinuation of dual antiplatelet therapy (6–11).
Drug-eluting stents delay healing and impair endotheli-
lization as evidenced in necropsy studies and clinical
nvestigations (12,13). Vessel remodeling (14) in concert
ith local drug release enhancing endothelial tissue factor
xpression (15,16) after DES implantation might result in a
rothrombotic milieu predisposing to late ST. Previously,
e reported on the frequency and timing of ST after the
nrestricted use of DES implantation in a cohort of 8,146
onsecutive patients treated at 2 academic institutions (10).
ate and very late ST was encountered steadily at an annual
ate of 0.6% with no evidence of diminution up to 3 years of
ollow-up. During extension of the follow-up period to 4
ears in the current study, we investigated whether the risk
f very late ST would change beyond 3 years, identified
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September 30, 2008:1134–40 DES Thrombosisorrelates of early as opposed to late ST, and assessed the
mpact of ST-related mortality after DES implantation on
verall mortality in the entire cohort.
ethods
tudy cohort, design, and follow-up. Between April
6, 2002, and December 31, 2005, a total of 8,146
onsecutive patients underwent percutaneous coronary
ntervention with the 2 Food and Drug Administration–
pproved DES at 2 academic referral hospitals in Swit-
erland and the Netherlands, comprising 3,823 patients
reated with sirolimus-eluting stents (SES) (Cypher,
ordis Corp., Johnson & Johnson, Warren, New Jersey)
nd 4,323 patients treated with paclitaxel-eluting stents
PES) (TAXUS Express2 or Liberté, Boston Scientific,
atick, Massachusetts). The use of the respective stent
latforms at the 2 institutions has been reported previ-
usly (10). For the present extended 4-year follow-up,
atients were again contacted 1 year after the last contact
ith specific questions addressing repeat hospital stay
nd major adverse cardiac events (MACE) with a health
uestionnaire. Patients who did not return the question-
aire were contacted by phone, at which time the
uestionnaire was completed. Moreover, survival data
ere obtained from municipal civil registries. If neces-
ary, medical records and discharge summaries from
ther institutions were systematically reviewed and pri-
ary care physicians were contacted for additional or
issing information. The median follow-up was 2.53
ears/patient, and a complete clinical follow-up was
chieved in 96.4% (n  7,857). The common database
as held and analyzed at the Institute of Social and
reventive Medicine, University of Bern, Bern, Switzer-
and. There was no industry involvement in the design,
onduct, or analysis of the study.
This study was approved by the local ethics committee in
oth hospitals and is in accordance with the Declaration of
elsinki. Written informed consent was obtained from all
atients.
efinitions. Definite ST was defined as follows:
. Presence of Thrombolysis In Myocardial Infarction
(TIMI) flow:
a. Grade 0 with occlusion originating in the peri-stent
region
b. Grade 1, 2, or 3 in the presence of a thrombus
originating in the peri-stent region. Angiographic
evidence of thrombus was defined as a discrete,
intraluminal filling defect with defined borders and
separated from the vessel wall.
And at least 1 of the following criteria had to be met:
. Acute ischemic symptoms (typical chest pain with dura-
tion 20 min)
. Ischemic electrocardiographic changes
a. ST-segment elevation in territory of implanted stent ab. ST-segment depression or
T-wave inversion in terri-
tory of implanted stent
. Typical rise and fall in cardiac
biomarkers (17).
All cases of definite ST were
eviewed independently by 2
xperienced interventional cardi-
logists, and in case of disagree-
ent, a consensus was estab-
ished between the 2 reviewers or
third interventional cardiologist
as consulted. Moreover, ST
as categorized into early (within
0 days), late (30 days and365
ays), and very late (365 days)
epending on the timing of oc-
urrence of the event. For the
efinition of probable ST, the
cademic Research Consor-
ium (ARC) criteria were ap-
lied (18).
The diagnosis of MI was based on the presence of new
waves in at least 2 contiguous leads with an elevated
reatine kinase-myocardial band fraction. In the absence
f pathologic Q waves, the diagnosis of MI was based on
n elevation in creatine kinase to more than twice the
pper limit of normal with an elevated creatine kinase-
yocardial band fraction of more than 3 times the upper
imit of normal. Premature discontinuation of antiplatelet
herapy was referred to as cessation of acetylsalicylic acid
ASA) or clopidogrel or both before the recommended
uration of prescription. A creatinine value 150 mol
r chronic hemodialysis qualified as definition of renal
mpairment.
nterventional procedure and antiplatelet prescription.
ll interventions were performed according to current
ractice guidelines for percutaneous coronary intervention.
he decision to choose a specific treatment strategy was left
o the discretion of the operator. Patients were prescribed
SA 100 mg once daily plus clopidogrel 75 mg/day (after a
oading dose of 300 or 600 mg) before or during baseline
oronary interventions. After the procedure, all patients
ere advised to maintain ASA 100 mg once daily lifelong.
n the Swiss institution, 12 months of clopidogrel therapy
as prescribed irrespective of the stent type used. In the
utch institution, PES-treated patients received at least 6
onths of clopidogrel (75 mg/day), whereas patients treated
ith SES were prescribed clopidogrel for at least 3 months,
nless 1 of the following was present (in which case
lopidogrel was maintained for at least 6 months): 3
ES implantations, total stent length36 mm, chronic total
cclusion, and bifurcations. In a minority of patients under oral
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ARC  Academic Research
Consortium
ASA  acetylsalicylic acid
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
MACE  major adverse
cardiac event
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TIMI  Thrombolysis In
Myocardial Infarctionnticoagulation therapy, a shorter duration of clopidogrel (e.g.,
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DES Thrombosis September 30, 2008:1134–40-month triple therapy with ASA, clopidogrel, and warfarin)
as recommended.
tatistical analysis. Continuous variables are expressed as
ean  SD or median values with the corresponding
nterquartile range. Dichotomous variables are expressed as
ounts and percentages. For comparison of continuous
ariables between SES and PES as well as early and late
hrombosis, a Student t test for continuous variables was
sed.
The incidence of ST was calculated in 2 different ways:
) incidence density, defined as the number of patients
ith ST divided by the total number of patient-years
nder observation (expressed as a number of events/100
atient-years); and 2) cumulative incidence, estimated
ccording to the Kaplan-Meier method and the log-rank
est for the differences in survival curve. Univariable and
ultivariable Cox proportional hazards models were used
o assess predictors of ST, with the following variables:
ge, gender, family history of cardiovascular disease,
iabetes, hypertension, current smoking, dyslipidemia,
enal impairment, left ventricular ejection fraction, acute
oronary syndrome (ACS) at presentation, stent type,
umber of stents, total stent length, average stent diam-
ter, bifurcation treatment, and prescribed duration of
lopidogrel. Statistical analyses were performed with
tata version 9 for Windows (Stata Corp., College
tation, Texas). All p values were 2-sided and values
0.05 were considered statistically significant.
esults
aseline clinical and procedural characteristics of patients
ith and without ST are summarized in Table 1. Compared
ith patients without ST, those suffering from definite ST
ere younger (59.4  12.1 years vs. 62.9  11.5 years, p 
.001), had a lower left ventricular ejection fraction (52 
2% vs. 55  12%, p  0.035) and more often an ACS
linical and Procedural Characteristics of Patients With and Witho
Table 1 Clinical and Procedural Characteristics of Patients Wit
Overall Population (n
Age (yrs), mean SD 62.8 11.
Male gender, % 74.5
Hypertension, % 46.5
Current smoking, % 36.8
Family history of CAD, % 28.1
Dyslipidemia, % 50.9
Diabetes, % 16.3
Left ventricular ejection fraction (%), mean  SD 55 12
Renal impairment, % 4.1
ACS at presentation, % 55.2
Bifurcation treatment, % 11.8
Sirolimus-eluting stent, % 47.9
Total stent length/patient (mm), mean  SD 36.3 25.
Number of stents/patient, mean  SD 1.96 1.2
Average stent diameter/patient (mm), mean  SD 2.94 0.3CS  acute coronary syndrome; CAD  coronary artery disease; ST  stent thrombosis.67.7% vs. 54.9%, p  0.001) at the time of stent implan-
ation, and had received longer (total stent length: 44.0 
8.8 mm vs. 36.1  25.5 mm, p  0.001) and more stents
number of stents: 2.33  1.71 vs. 1.95  1.21, p  0.001),
hich were smaller in diameter (2.88 0.32 mm vs. 2.94
.38 mm, p  0.048). The status of antiplatelet therapy as
ecorded during early and late and very late ST is summa-
ized in Figure 1.
ncidence and time course of ST. During a follow-up
eriod of 4 years, definite ST was encountered in 192 of
,146 patients after a median of 56 (interquartile range 4 to
93) days (Fig. 2). Early ST was observed in 92 (48%), late
T in 31 (16%), and very late ST in 69 (36%) of 192
atients. Definite ST occurred with an incidence density of
.0/100 patient-years and a cumulative incidence of 3.3% at
years of follow-up. The hazard of late ST (between 30
ays and 1 year) amounted to 0.46% (95% confidence
nterval [CI]: 0.32% to 0.65%), the hazard of very late ST
between 1 and 4 years) to 0.57% (95% CI: 0.45% to
Figure 1 Status of Antiplatelet Treatment
at Time of Definite Stent Thrombosis
Proportion of patients with early and late stent
thrombosis treated with dual, single, or no antiplatelet therapy.
finite ST
Without Definite ST
146) ST (n  192) No ST (n  7,954) p Value
59.4 12.1 62.9 11.5 0.001
75.0 74.5 0.88
42.2 46.6 0.23
41.7 36.7 0.16
29.2 28.1 0.75
50.0 50.9 0.81
20.8 16.2 0.09
52 12 55 12 0.035
2.6 4.2 0.48
67.7 54.9 0.001
17.9 11.6 0.06
43.2 48.0 0.19
44.0 38.8 36.1 25.5 0.001
2.33 1.71 1.95 1.21 0.001
2.88 0.32 2.94 0.38 0.048ut De
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September 30, 2008:1134–40 DES Thrombosis.72%), and the hazard of the combined rate for late and
ery late ST (between 30 days and 4 years) was 0.53% (95%
I: 0.44% to 0.64%)/year. The rate of definite and probable
T after 4 years amounted to 5.7% (95% CI: 5.15% to
.39%) with an incidence of 3.68% (95% CI: 3.29% to
.12%) after 30 days and 4.09% (95% CI: 3.67% to 4.55%)
fter 1 year (Fig. 2).
Baseline demographic data for SES- and PES-treated
atients differed widely (Table 2). The cumulative incidence
f ST up to 3.5 years amounted to 2.7% for SES-treated
nd 3.6% for PES-treated patients (HR: 0.7; 95% CI: 0.53
o 0.95, p  0.02) (Fig. 3A). Whereas early ST occurred
ith similar frequency in SES- (1.0%) and PES-treated
Figure 2 Cumulative Incidence of Definite ST in
8,146 Patients During a 4-Year Follow-Up Period
PCI  percutaneous coronary intervention; ST  stent thrombosis.
Clinical and Procedural Characteristics of Patie
Table 2 Clinical and Procedural Characteris
Age (yrs), mean  SD
Male gender, %
Hypertension, %
Current smoking, %
Family history of CAD, %
Dyslipidemia, %
Diabetes, %
Left ventricular ejection fraction (%), mean SD
Renal impairment, %
ACS at presentation, %
Bifurcation treatment, %
Total stent length/patient (mm), mean  SD
Number of stents/patient, mean  SD
Average stent diameter/patient (mm), mean  SD
Duration of clopidogrel prescription (days), mean  SDPES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s); other abbrFigure 3 Cumulative Incidence of Definite ST Stratification
(A) Cumulative incidence of definite stent thrombosis (ST) stratified by stent
type. (B) Cumulative incidence of definite ST stratified by stent type and treat-
ment site. PCI  percutaneous coronary intervention; PES  paclitaxel-eluting
stent(s); SES  sirolimus-eluting stent(s).nts Stratified by Stent Type
tics of Patients Stratified by Stent Type
SES (n  3,823) PES (n  4,323) p Value
62.6 11.4 63.0 11.5 0.31
74.9 74.2 0.51
41.9 51.6 0.0001
44.9 29.5 0.0001
29.0 27.3 0.09
55.8 47.3 0.0001
18.3 14.6 0.0001
54 12 55 12 0.01
4.3 3.9 0.58
52.1 58.0 0.0001
10.3 12.3 0.09
33.8 23.0 38.6 28.1 0.0001
1.87 1.14 2.03 1.30 0.0001
2.86 0.32 3.00 0.40 0.0001
144 120 194 80 0.0001eviations as in Table 1.
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DES Thrombosis September 30, 2008:1134–401.3%) patients (HR: 0.76; 95% CI: 0.50 to 1.15, p 0.19),
ate and very late ST occurred with an annual rate of 0.44%
95% CI: 0.33% to 0.59%) after SES and 0.63% (95% CI:
.49% to 0.83%) after PES implantation (HR: 0.66; 95%
I: 0.44 to 0.99, p  0.047). A stratified analysis according
o treatment site revealed a similar frequency and time
ourse of definite ST after SES (Bern: 2.9% vs. Rotterdam:
.4%, p  0.49) and PES (Bern: 3.1% vs. Rotterdam: 3.9%,
 0.83) implantation at both institutions (Fig. 3B).
redictors of ST. The results of multivariate analyses to
dentify overall, early, and late definite ST are summarized
n Table 3. Acute coronary syndrome at the time of stent
mplantation (HR: 1.81; 95% CI: 1.32 to 2.49), diabetes
HR: 1.61; 95% CI: 1.11 to 2.33), younger age (HR: 0.98;
5% CI: 0.96 to 0.99), and use of PES (HR: 1.51; 95% CI:
.10 to 2.04) were independent predictors of overall ST.
iabetes (HR: 1.96; 95% CI: 1.18 to 3.28) was the only
redictor of early ST, whereas ACS at time of stent
mplantation (HR: 2.21; 95% CI: 1.39 to 3.51), younger age
HR: 0.97; 95% CI: 0.95 to 0.99), and use of PES (HR:
.67; 95% CI: 1.08 to 2.56) were independently associated
ith an increased risk of late ST.
ong-term clinical outcome. Mortality after definite ST
mounted to 15.6% at 2 years and tended to be higher in
atients suffering from early (20.3%) as opposed to late and
ery late ST (10.4%) (Fig. 4). At 4 years of follow-up, rates
f death, MI, and the composite of death or MI were
0.6%, 4.6%, and 14.6%, respectively, in the overall popula-
ion (Fig. 5). During the entire observation period of 4 years,
7 patients suffering from definite ST subsequently died.
eath after the diagnosis of definite ST occurred in 0.4% of
he entire population and accounted for 3.9% of all 702 deaths.
iscussion
he results of the present study indicate a continuous hazard of
ate and very late ST at an annual rate of 0.4% to 0.6%
xtending to 4 years after DES implantation. The only
ndependent predictor of early ST was diabetes, whereas ACS,
ounger age, and use of PES were independently associated
azard Ratio and 95% CI for Risk Factorsssociated With Definite ST During the Entireoll w-Up Per od From Multivariable C x Regression
Table 3
Hazard Ratio and 95% CI for Risk Factors
Associated With Definite ST During the Entire
Follow-Up Period From Multivariable Cox Regression
Variables Hazard Ratio 95% CI
ACS at presentation 1.8 1.3–2.5
Diabetes 1.6 1.1–2.3
Number of stents/patient 1.2 0.95–1.4
Current smoking 1.1 0.78–1.5
Family history of CAD 1.0 0.73–1.4
Total stented length/patient 1.0 1.00–1.01
Age 0.98 0.96–0.99
Dyslipidemia 0.95 0.70–1.28
Female 0.89 0.63–1.25
Hypertension 0.85 0.62–1.16
Use of PES 1.67 1.08–2.56I  confidence interval; other abbreviations as in Tables 1 and 2.ith an increased risk of late ST. Mortality due to definite ST
ccounted for only a small fraction of overall mortality.
Autopsy studies and clinical investigations using angios-
opy and assessment of endothelial function indicate that DES
elay healing and impair endothelialization (12,13,
9–22). Intravascular ultrasound studies demonstrate a higher
ncidence of stent malapposition and evidence of vessel remod-
ling after DES implantation in patients with very late ST
14). Furthermore, drugs released from the drug-polymer
ombination might be thrombogenic on their own, because
oth sirolimus and paclitaxel enhance endothelial tissue factor
xpression, the principal activator of the coagulation cascade
hat activates factors IX and X (15,16). Therefore, it has been
uggested that DES might create a prothrombotic milieu
redisposing to thrombotic stent occlusion.
Previously, we reported the phenomenon of late ST after
ES implantation occurring continuously without diminu-
Figure 4 Cumulative Incidence of Death in Patients With
Definite ST Stratified According to Early and Late ST
ST  stent thrombosis.
Figure 5 Cumulative Incidence of Ischemic Adverse Events
in 8,146 Patients During 4 Years of Follow-Up
MI  myocardial infarction; PCI  percutaneous
coronary intervention; ST  stent thrombosis.
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September 30, 2008:1134–40 DES Thrombosision up to 3 years of follow-up in a large cohort of
onsecutive patients treated with the unrestricted use of
ES (10). The present study extends these findings to a
onger-term follow-up and shows that the steady annual rate
f 0.4% to 0.6% remains unchanged between 3 and 4 years
f follow-up. A continuous linear hazard of late ST com-
arable to the present study has been corroborated more
ecently in the extended follow-up of 21,717 DES-treated
atients included in the SCAAR (Swedish Coronary An-
iography and Angioplasty Registry) with an annual rate of
T of 0.5% during a follow-up of 2 years (23,24). Moreover,
everal systematic reviews reported a significantly higher
ate of very late ST in disfavor of both SES and PES
ompared with BMS, although the overall rate of ST was
ot different between the different stent types (3,4,25).
ccordingly, very late ST is a distinct entity complicating
he use of DES, and arterial healing remains incomplete up
o 4 years after DES implantation in humans.
Although late and very late ST complicated the clinical
ourse of both DES types, it was more frequent with PES
han SES, and use of PES emerged as independent of late
T. Of note, PES was implanted in more complex lesions in
his cohort, whereas SES had been used earlier than PES,
nd subsequently the length of follow-up was different
etween the 2 devices, which might have biased the results
n disfavor of PES. Yet, Bavry et al. (7) made a similar
bservation and found the risk of very late ST more
ronounced with PES (5.9 of 1,000 patient-years) than SES
3.6 of 1,000 patient-years) in a meta-analysis of 14 trials
ith 6,675 patients. A meta-analysis directly comparing
ES (4,391 patients) with PES (4,304 patients) also re-
orted a higher risk of protocol-defined ST with PES
1.9%) than SES (1.2%; HR: 0.66, 95% CI: 0.46 to 0.94,
 0.02) (26). Finally, a network meta-analysis of 38 trials
omparing BMS, SES, and PES reported an increased risk
f late ST with PES compared with BMS (HR: 2.11; 95%
redibility interval: 1.2 to 4.2, p  0.02), whereas the risk
as less pronounced with SES (HR 1.1; 95% credibility
nterval: 0.6 to 2.3, p  0.71) (5). It can only be speculated
hether the different drug-release kinetics, distribution
ithin the vessel wall, mechanisms of action, inhomogene-
ty of strut coverage, or design of the stent platforms impact
n the incidence and time course of late ST.
Previous studies identified clinical characteristics such as
remature discontinuation of antiplatelet therapy (27–29),
CS (10,30), diabetes (10,27,30), and renal failure (27,28)
s independent risk factors of DES-associated ST. In
ddition, lesion characteristics including smaller reference
essel diameter, stent length (29), thrombus burden (31),
nd bifurcation lesions (27,28) were identified as predictive
f ST. The present study not only confirms the hazard
elated to diabetes and ACS in the largest cohort of patients
ith definite ST to date but also identifies diabetes as a
redictor of early ST and ACS as a predictor of late ST. The
easons for a predisposition of diabetic patients to early ST
ight be related to smaller vessel size (32), longer lesion mength, a higher rate of residual dissections, and an increased
latelet aggregation (11,33). Conversely, patients with ACS
ight be predisposed to late and very late ST due to a higher
hrombus burden at the time of stent implantation (31), which
pon dissolution might result in late acquired stent malappo-
ition and altered flow dynamics around stent struts (14).
The contribution of definite ST to overall mortality was
mall in the present study (5%). A similar observation has
een made in a pooled analysis of pivotal trials comparing
ES with BMS (25), where mortality due to ST accounted
or 10% of overall mortality. It might be speculated that
he overall outcome regarding death or MI of patients
reated by percutaneous coronary interventions might be
etermined in large part by causes other than target lesion
evascularization or ST. Along this line, a pooled analysis of
randomized trials comparing SES with BMS in 1,748
atients found that the majority of death or MI in both
tent groups was unrelated to either target lesion revascu-
arization or ST, suggesting another etiology, such as disease
rogression (34). However, it is important to note that the
efinition of definite ST requiring angiographic or autopsy
onfirmation of thrombotic stent occlusion leads to a
onsiderable underestimation of the true incidence of ST-
elated mortality. Because only those patients reaching the
atheterization laboratory alive qualify for the diagnosis of
efinite ST, all deaths before angiographic or autopsy
onfirmation are missed and not classified as “definite
T”–related. In other words, the presented data only reflect
he mortality toll of definite ST after initial survival.
tudy limitations. The findings of this study have to be
nterpreted in light of several limitations. First, the study
as nonrandomized, with the decision regarding stent type
nd antiplatelet therapy largely determined by local institu-
ional practice. The principal purpose was to investigate the
ncidence and time course of definite ST in unselected
atients treated with DES during long-term follow-up
ather than a comparison of ST as encountered after BMS
mplantation. This is an observational study, which suffers
rom confounding by indication. The SES and PES were
sed in both centers during different time periods, and PES
as available for commercial use 1 year later than SES. This
ight have resulted in bias due to differences in follow-up.
ue to the continuous enrollment of patients into this
egistry between 2002 and 2005, not all patients had
ompleted the 4-year follow-up. Accordingly, estimates of
he risk of ST are less precise during later time points, and
he data should be carefully interpreted by considering the
orresponding CIs. Second, the data were obtained from a
atient population at 2 tertiary care centers with a high
umber of stents/patient, a small average stent diameter,
nd an overall long total stent length, which might not apply
o institutions with a more restricted DES use. Third, it is
ossible that some ST went undetected in our study despite
ur attempts at an active surveillance of harms. In addition,
he focus of the present study was on definite ST, which
ight have led to an underestimation of the actual incidence
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DES Thrombosis September 30, 2008:1134–40f ST as well as mortality related to definite ST. The latter
equires angiographic or autopsy confirmation of throm-
otic stent occlusion and therefore ignores any death with-
ut these prerequisites. However, the definition is in line
ith previous reports from our group on ST either after
ES or BMS implantation and allows for appropriate
omparisons. Moreover, the composite of definite and
robable ST, suggested as a useful parameter to avoid
nderestimation and overestimation of ST, is provided in
he present study as are the ischemic end points of death
nd MI. Finally, only the prescribed duration of anti-
latelet therapy was available in the present study,
hereas the exact duration of dual antiplatelet therapy
ould not reliably be ascertained in the whole patient
opulation. Therefore, it cannot be excluded that we
issed an important relation between the actual duration
f thienopyridine therapy and ST.
onclusions
ate ST is a distinct entity complicating the use of DES and
ccurs steadily at an annual rate of 0.4% to 0.6% for up to
years of follow-up. Diabetes is an independent predictor
f early ST, whereas ACS, younger age, and use of PES are
ssociated with late ST.
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